Granules India Limited submitted its unaudited financial results for the first quarter of FY 2026-2027 (Q1FY27) to the stock exchanges on July 21, 2026. This press release, addressed to analysts and investors, was filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance (Consolidated, INR Mn)

A summary of the key financial figures for Q1FY27, with comparisons to the previous quarter (Q4FY26) and the year-ago quarter (Q1FY26), is provided:

| Metric | Q1FY27 | Q4FY26 | QoQ Growth | Q1FY26 | YoY Growth |

| Revenue from Operations | 14,768 | 14,706 | 0% | 12,101 | 22% |

| EBITDA | 3,389 | 3,521 | -4% | 2,467 | 37% |

| EBITDA Margin | 23% | 24% | - | 20% | - |

| PBT Before Exceptional Item | 2,404 | 2,464 | -2% | 1,704 | 41% |

| Exceptional Item / (Income) | 0 | (159) | - | 259 | - |

| PAT | 1,800 | 2,016 | -11% | 1,126 | 60% |

| PAT Margin | 12% | 14% | - | 9% | - |

Business and Operational Highlights

  • Revenue Breakdown by Geography: North America contributed 72% of revenue in Q1FY27 (77% in Q1FY26). Europe contributed 16% of revenue in Q1FY27 (13% in Q1FY26).
  • Revenue Breakdown by Segment: Finished Dosages (FD) contributed 74%, Active Pharmaceuticals Ingredients (API) contributed 13%, Pharmaceutical Formulation Intermediates (PFI) contributed 9%, and Peptides CDMO contributed 4% of total revenue from operations for Q1FY27.
  • Return on Capital Employed (ROCE): Improved to 18.0% in Q1FY27 from 17.6% in FY26.
  • Debt Position: Net debt stood at ₹1,012 Mn, representing a reduction of ₹8,467 Mn from Q1FY26. The Net debt to EBITDA ratio was 0.07x.

Management Commentary

Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, commented on the results. He stated that Q1 FY27 marked an important step forward as foundations from FY26 translated into greater execution confidence and business resilience. The company's focus remains on regulatory and quality excellence, portfolio transformation toward complex products, and geographic diversification. He noted that external cost pressures and supply chain volatility require continuous management for the next couple of quarters. The company is continuing to invest in R&D (largely towards Complex Gx), digitalization, operational excellence, sustainability, and talent to support long-term value creation. He expressed confidence in the company's ability to deliver sustainable growth.

Company Background

The press release includes a standard boilerplate describing Granules India Limited as a vertically integrated pharmaceutical company headquartered in Hyderabad. It was incorporated in 1991 and manufactures Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs), and offers Peptides CDMO services. Its products are distributed to over 300 customers and it has a presence in over 80 countries. The company has 10 manufacturing facilities (7 in India, 2 in the USA, 1 in Switzerland) with various regulatory approvals.

Safe Harbour Statement

The document concludes with a standard safe harbour statement noting that it contains forward-looking statements subject to uncertainties and changes in circumstances, and the company disclaims any obligation to update them.